Kleo Pharmaceuticals

Please note: The information displayed on this page might be outdated.
Kleo Pharmaceuticals: Kleo Pharmaceuticals is advancing the field of immunotherapy by developing small molecules that emulate biologics. Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs) are designed to direct your immune system to fight specific disease causing cells. They are however much lower in molecular weight than therapeutic antibodies and thereby offer clinicians targeted treatment options that are potentially safer, more effective, and more easily deliverable than their protein-based counterparts. Both ARMs and SyAMs are adaptable platforms that can be deployed against cancer and infectious diseases.
Based in...
US - New England
25 Science Park
Suite 235
150 Munson Street
New Haven, CT 06511
United States

Company Participants at Fall Private Company Showcase 2020

Doug Manion
Kleo Pharmaceuticals, CEO
Doug is CEO of Kleo Pharmaceuticals. He has 20 years’ experience in drug development. He was the Senior Vice President, Head of Specialty Development and Head of Japan and China R&D at BMS until October 2016. He had leadership roles at BMS overseeing various therapeutic areas including virology, immunoscience, neurology, cardiology, metabolic diseases, genetically-defined diseases and fibrosis since joining in 2005. From 2001 to 2005, he was Vice President of Clinical Development and Medical Affairs for HIV/AIDS at GSK. He started his career at DuPont Pharmaceuticals in 1997. He is Board Certified in Internal Medicine and completed his Fellowship in Infectious Diseases in Ottawa Canada and a clinical and bench research fellowship at Massachusetts General Hospital and Harvard Medical School. Doug also serves on the Board of Directors of Celleron Therapeutics.